Peptide research profile
Semaglutide
Also known as Ozempic · Rybelsus · sema · Wegovy
Large randomized trials show clinically meaningful weight reduction. In adults with established cardiovascular disease and overweight or obesity without diabetes, SELECT also found fewer major cardiovascular events. Results and indications differ by product and formulation.
High evidenceFDA approved
- Evidence maturity
- Established record
- Regulatory status
- FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 3
- Side-effect records
- 2,998Named most often: Nausea · Constipation · Vomiting
Educational. Not medical advice.
Summary
A GLP-1 receptor agonist with FDA-approved products for specific metabolic and cardiovascular indications.
What is Semaglutide being studied for?
Weight management and cardiovascular risk
How is it thought to work?
Activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, reducing glucagon, lowering appetite and caloric intake, and delaying gastric emptying.
Recorded outcomes
2,998 side-effect records on Semaglutide
Free account3 graded outcomes and 3 sources for Semaglutide.
Outcome table and every source open with a free account. No card.
Update history
Updated
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.